| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical Research Service of the Seattle Department of Veterans’ Affairs Medical Center, and Division of Pulmonary/Critical Care Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98101
CD14, a pattern recognition receptor found on myeloid cells, is a critical component of the innate immune system that mediates local and systemic host responses to Gram-negative and Gram-positive bacterial products. Previous studies in normal animals have tested the effect of CD14 blockade on the systemic response to i.v. LPS. The goals of the study were to determine whether CD14 blockade protected against the deleterious systemic response associated with Escherichia coli pneumonia and to determine whether this strategy affected the pulmonary response to tissue infection. Rabbits were pretreated with either anti-CD14 mAb or isotype control mAb at 2.5 mg/kg. E. coli (1 x 109 CFU) was inoculated into the lungs, and the animals were observed for either 4 or 24 h. The blockade of CD14 improved the mean arterial blood pressure (p = 0.001) and decreased the i.v. fluid requirements (p = 0.01). Although this therapy protected the vascular compartment, rabbits treated with anti-CD14 mAb had increased bacterial burdens in the bronchoalveolar lavage fluid recovered from the instilled lung (p = 0.005) and widened alveolar-arterial oxygen difference. Blockade of CD14 prevents the deleterious systemic responses that occur in sepsis; however, other measures are necessary to control bacterial proliferation at the primary site of infection.
This article has been cited by other articles:
|
|
 |
|
  T. Roger, C. Froidevaux, D. Le Roy, M. K. Reymond, A.-L. Chanson, D. Mauri, K. Burns, B. M. Riederer, S. Akira, and T. Calandra Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4 PNAS, February 17, 2009; 106(7): 2348 - 2352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Su, M. Johansen, M. R. Looney, E. J. Brown, and M. A. Matthay CD47 Deficiency Protects Mice from Lipopolysaccharide-Induced Acute Lung Injury and Escherichia coli Pneumonia J. Immunol., May 15, 2008; 180(10): 6947 - 6953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Mizgerd Acute Lower Respiratory Tract Infection N. Engl. J. Med., February 14, 2008; 358(7): 716 - 727. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Metkar, S. Awasthi, E. Denamur, K. S. Kim, S. C. Gangloff, S. Teichberg, A. Haziot, J. Silver, and S. M. Goyert Role of CD14 in Responses to Clinical Isolates of Escherichia coli: Effects of K1 Capsule Expression Infect. Immun., November 1, 2007; 75(11): 5415 - 5424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Daubeuf, J. Mathison, S. Spiller, S. Hugues, S. Herren, W. Ferlin, M. Kosco-Vilbois, H. Wagner, C. J. Kirschning, R. Ulevitch, et al. TLR4/MD-2 Monoclonal Antibody Therapy Affords Protection in Experimental Models of Septic Shock J. Immunol., November 1, 2007; 179(9): 6107 - 6114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Brass, J. W. Hollingsworth, E. McElvania-Tekippe, S. Garantziotis, I. Hossain, and D. A. Schwartz CD14 is an essential mediator of LPS-induced airway disease Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L77 - L83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Dessing, S. Knapp, S. Florquin, A. F. de Vos, and T. van der Poll CD14 Facilitates Invasive Respiratory Tract Infection by Streptococcus pneumoniae Am. J. Respir. Crit. Care Med., March 15, 2007; 175(6): 604 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Stearns-Kurosawa, F. Lupu, F. B. Taylor Jr., G. Kinasewitz, and S. Kurosawa Sepsis and Pathophysiology of Anthrax in a Nonhuman Primate Model Am. J. Pathol., August 1, 2006; 169(2): 433 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Genth-Zotz, S. von Haehling, A. P. Bolger, P. R. Kalra, R. Wensel, A. J.S. Coats, H.-D. Volk, and S. D. Anker The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure Eur J Heart Fail, June 1, 2006; 8(4): 366 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Martin and C. W. Frevert Innate Immunity in the Lungs Proceedings of the ATS, December 1, 2005; 2(5): 403 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jeyaseelan, R. Manzer, S. K. Young, M. Yamamoto, S. Akira, R. J. Mason, and G. S. Worthen Toll-IL-1 Receptor Domain-Containing Adaptor Protein Is Critical for Early Lung Immune Responses against Escherichia coli Lipopolysaccharide and Viable Escherichia coli J. Immunol., December 1, 2005; 175(11): 7484 - 7495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Echchannaoui, K. Frei, M. Letiembre, R. M. Strieter, Y. Adachi, and R. Landmann CD14 deficiency leads to increased MIP-2 production, CXCR2 expression, neutrophil transmigration, and early death in pneumococcal infection J. Leukoc. Biol., September 1, 2005; 78(3): 705 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R.-E.-I. Benhnia, D. Wroblewski, M. N. Akhtar, R. A. Patel, W. Lavezzi, S. C. Gangloff, S. M. Goyert, M. J. Caimano, J. D. Radolf, and T. J. Sellati Signaling through CD14 Attenuates the Inflammatory Response to Borrelia burgdorferi, the Agent of Lyme Disease J. Immunol., February 1, 2005; 174(3): 1539 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Lin, C. W. Frevert, O. Kajikawa, M. M. Wurfel, K. Ballman, S. Mongovin, V. A. Wong, A. Selk, and T. R. Martin Differential Regulation of Membrane CD14 Expression and Endotoxin-Tolerance in Alveolar Macrophages Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2): 162 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Axtelle and J. Pribble An overview of clinical studies in healthy subjects and patients with severe sepsis with IC14, a CD14-specific chimeric monoclonal antibody Innate Immunity, December 1, 2003; 9(6): 385 - 389. [Abstract] [PDF]
|
|
|
|
|
|
S. Tasaka, A. Ishizaka, W. Yamada, M. Shimizu, H. Koh, N. Hasegawa, Y. Adachi, and K. Yamaguchi Effect of CD14 Blockade on Endotoxin-Induced Acute Lung Injury in Mice Am. J. Respir. Cell Mol. Biol., August 1, 2003; 29(2): 252 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-W. Lee, M. J. Paape, T. H. Elsasser, and X. Zhao Recombinant Soluble CD14 Reduces Severity of Intramammary Infection by Escherichia coli Infect. Immun., July 1, 2003; 71(7): 4034 - 4039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hiki, Y. Mimura, T. Ogawa, J. Kojima, F. Hatao, and M. Kaminishi Pathophysiological relevance of the CD14 receptor in surgical patients: biological activity of endotoxin is regulated by the CD14 receptor Innate Immunity, December 1, 2001; 7(6): 461 - 466. [Abstract] [PDF]
|
|
|
|
|
|
C. Retini, T. R. Kozel, D. Pietrella, C. Monari, F. Bistoni, and A. Vecchiarelli Interdependency of Interleukin-10 and Interleukin-12 in Regulation of T-Cell Differentiation and Effector Function of Monocytes in Response to Stimulation with Cryptococcus neoformans Infect. Immun., October 1, 2001; 69(10): 6064 - 6073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Matute-Bello, C. W. Frevert, W. C. Liles, M. Nakamura, J. T. Ruzinski, K. Ballman, V. A. Wong, C. Vathanaprida, and T. R. Martin Fas/Fas Ligand System Mediates Epithelial Injury, but Not Pulmonary Host Defenses, in Response to Inhaled Bacteria Infect. Immun., September 1, 2001; 69(9): 5768 - 5776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Axtelle and J. Pribble IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis Innate Immunity, August 1, 2001; 7(4): 310 - 314. [Abstract] [PDF]
|
|
|
|
|
|
S. J. Ebong, S. M. Goyert, J. A. Nemzek, J. Kim, G. L. Bolgos, and D. G. Remick Critical Role of CD14 for Production of Proinflammatory Cytokines and Cytokine Inhibitors during Sepsis with Failure To Alter Morbidity or Mortality Infect. Immun., April 1, 2001; 69(4): 2099 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Verbon, P. E. P. Dekkers, T. ten Hove, C. E. Hack, J. P. Pribble, T. Turner, S. Souza, T. Axtelle, F. J. Hoek, S. J. H. van Deventer, et al. IC14, an Anti-CD14 Antibody, Inhibits Endotoxin-Mediated Symptoms and Inflammatory Responses in Humans J. Immunol., March 1, 2001; 166(5): 3599 - 3605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Martin Recognition of Bacterial Endotoxin in the Lungs Am. J. Respir. Cell Mol. Biol., August 1, 2000; 23(2): 128 - 132. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
